Supriya Lifescience Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Pharmaceuticals & Biotechnology | Market Cap: ₹6.5K Cr
Supriya Lifescience targets a revenue of Rs. Supriya Lifescience targets a revenue of around Rs.
From Supriya Lifescience Ltd's Q1 FY27 earnings-call transcript · updated 26 Aug 2026.
Price
₹782
Market Cap
₹6.5K Cr
P/E Ratio
32.6
Revenue Rank
Margin Rank
How does Supriya Lifescience Ltd rank in Pharmaceuticals & Biotechnology?
Compare Supriya Lifescience Ltd against every Pharmaceuticals & Biotechnology company this quarter on revenue, margins and earnings-call signals.
Supriya Lifescience Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹277 Cr, net profit ₹74 Cr.
Full financials →📊 Revenue & Sales Performance
Rank 2- →Supriya Lifescience targets a revenue of Rs. 1,000 crores by FY '27, reflecting strong demand and robust product pipeline.
- →The company expects a CAGR growth of about 20% year-on-year beyond FY '27, supported by new products and capacity expansions.
- →Q1 FY '27 revenue was Rs. 190 crores, showing 31% YoY growth despite water scarcity issues.
- →Growth is anticipated to accelerate in the second half of FY '27 due to scaling-up of liquid anesthetic products, cardiovascular drugs, and launch of contrast media products.
- →Continued addition of new products, new therapy verticals, and CMO-CDMO collaborations at API and formulation levels will support sustained growth.
- →Expansion at Ambernath facility (finished formulations) and capacity building at the Patalganga plant also underpin future growth.
- →Growth may exceed 20%, subject to regulatory approvals and successful commercial ramp-ups.
📈 Profitability & Margins
Rank 3- →Supriya Lifescience targets a revenue of around Rs. 1,000 crores by FY '27, reflecting strong demand and new product launches.
- →Management anticipates maintaining EBITDA margins in the range of 33% to 35% over the next 3-4 years.
- →PAT margin guidance stands around 25%.
- →Growth expected to be non-linear quarterly but robust over the medium term, supported by new therapies, vertical expansions (CMO-CDMO), and capacity additions like Patalganga facility.
- →CAGR growth of about 20% year-on-year expected beyond FY '27, with potential for acceleration depending on regulatory approvals and market traction.
- →Margin expansion beyond current levels unlikely in near term due to CMO-CDMO focus and semi-regulated market scale-up phases.
🏗️ Capital Expenditure Plans
Yes- →**Patalganga Facility Investment**: Phase-1 CapEx earmarked at around Rs. 200 crores, including two API/advanced intermediate blocks and two formulation blocks. Construction started with boundary walls already underway. API block prioritized initially due to nearing capacity exhaustion at the Lote site. Formulation blocks to be developed phase-wise (Page 4, 5, 12).
- →**Isambe Project**: Initial phase CapEx estimated at Rs. 200 crores with potential for larger investment in subsequent phases (Page 17).
- →**Ambernath Facility**: Depreciation expected at Rs. 14-15 crores annually; facility recently started contributing to revenue and scheduled for EU audit in November (Page 10, 12).
- →**Maintenance and Small Projects**: Ongoing smaller CapEx for maintenance, formulation plans, and scale-up (Page 5, 14).
- →**Automation and R&D Expansion**: Investments in R&D expansion and system implementations including SAP and quality management systems (Page 16, 19).
💰 Fundraising & Capital Structure
No information- →No explicit mention of new fundraising plans through debt or equity in the provided transcript.
- →The company reported having around Rs. 150 crores in fixed deposits and mutual funds as cash reserves.
- →CapEx plans include Rs. 200 crores for Phase-1 of the Patalganga project, funded likely through existing resources and internal accruals.
- →The company stated no utilization of working capital limits except for letters of credit and bank guarantees, indicating stable liquidity.
- →No direct comments on plans to raise new capital via debt or equity during the discussed period or in the near future.
📋 Order Book & Pipeline
Yes- →The company is scaling its CDMO-CMO business with promising progress.
- →They are very close to signing a term sheet for a large anesthetic CDMO contract, expected to be announced next quarter.
- →Qualification work and quality approvals for this contract are largely completed.
- →New product launches, including anesthetic liquids and cardiovascular drugs, are expected to contribute to order growth.
- →The company anticipates a robust product pipeline supporting sustained demand across various therapeutic segments.
- →Revenue target of approximately Rs. 1,000 crores by FY '27 remains on track, indicating strong order inflow.
- →Growth is expected to be non-linear, influenced by product ramp-ups and market conditions.
- →No explicit numerical figure on total current pending orders or backlog was provided within the disclosed pages.
Key Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Continue your research
What Supriya Lifescience Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sigachi Industries Ltd (Q1 FY27)
Q1 FY27 sales were INR121.27 crores with 76.8% overall capacity utilization; planned to increase utilization quarter-on-quarter. Key concall takeaways from…
- Gujarat Themis Biosyn Ltd (Q1 FY27)
Raising equity (~INR 1,000 crores) and debt (~INR 2,000 crores) planned to support growth. Key concall takeaways from Gujarat Themis Biosyn Ltd's Q1 FY27…
- Fredun Pharmaceuticals Ltd (Q1 FY27)
Long-term growth also supported by capacity expansion (INR30-40 crore CapEx per year) and planned acquisitions. Key concall takeaways from Fredun…
- Sai Parenterals Ltd (Q1 FY27)
750 crores with EBITDA margin around 17%, weighted towards the second half. Key concall takeaways from Sai Parenterals Ltd's Q1 FY27 earnings call — and how it…
Frequently Asked Questions
What were Supriya Lifescience Ltd Q1 FY27 results?
Supriya Lifescience targets a revenue of Rs. Supriya Lifescience targets a revenue of around Rs.
What is Supriya Lifescience Ltd share price analysis?
Supriya Lifescience Ltd currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 32.6 with a market cap of ₹6,482 Cr. Investors should review the full earnings analysis for detailed insights.
Is Supriya Lifescience Ltd planning capital expenditure?
Patalganga Facility Investment**: Phase-1 CapEx earmarked at around Rs.
Keep Supriya Lifescience Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.